Adjuvant Treatment Modalities, Prognostic Predictors and Outcomes of Uterine Carcinosarcomas
3
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to evaluate the clinicopathological characteristics, treatment,and prognosis of uterine carcinosarcoma (UC). Materials and MethodsA retrospective review of three cancer registry databases in Turkey was conducted foridentification of patients diagnosed with UC between January 1, 1996, and December 31,2012. We collected clinicopathological data in order to evaluate factors important in disease-free survival (DFS) and overall survival (OS). ResultsA total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy(RT), the median DFS and OS was 44 months and 55 months, respectively, compared to34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone(hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR,2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFSand OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively,compared to 23.5 months and 24.5 months, respectively, in patients receivingadjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI,0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation ofGynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant associationwith poor OS. ConclusionIn patients with early or advanced stage UC, adjuvant CT with RT is associated with improvedDFS and OS, as compared to CT or RT alone.
Abstract
Purpose The purpose of this study is to evaluate the clinicopathological characteristics, treatment,and prognosis of uterine carcinosarcoma (UC). Materials and MethodsA retrospective review of three cancer registry databases in Turkey was conducted foridentification of patients diagnosed with UC between January 1, 1996, and December 31,2012. We collected clinicopathological data in order to evaluate factors important in disease-free survival (DFS) and overall survival (OS). ResultsA total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy(RT), the median DFS and OS was 44 months and 55 months, respectively, compared to34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone(hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR,2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFSand OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively,compared to 23.5 months and 24.5 months, respectively, in patients receivingadjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI,0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation ofGynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant associationwith poor OS. ConclusionIn patients with early or advanced stage UC, adjuvant CT with RT is associated with improvedDFS and OS, as compared to CT or RT alone.
참고문헌 (19)
- Arrastia CD, "Uterine carcinosarcomas : incidence and trends in management and survival", Gynecol Oncol, 65, pp.158~163 (1997)
- Berek JS, "Berek and Hacker's gynecologic oncology", pp.2010, Wolters Kluwer
- Schweizer W, "Prognostic factors for malignant mixed mullerian tumors of the uterus", Int J Gynecol Pathol, 9, pp.129~136 (1990)
- Cimbaluk D, "Uterine carcinosarcoma : immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets", Gynecol Oncol, 105, pp.138~144 (2007)
- Galaal K, "Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma", Eur J Obstet Gynecol Reprod Biol, 143, pp.88~92 (2009)
- Vorgias G, "The role of lymphadenectomy in uterine carcinosarcomas(malignant mixed mullerian tumours) : a critical literature review", Arch Gynecol Obstet, 282, pp.659~664 (2010)
- El-Nashar SA, "Uterine carcinosarcoma", Clin Obstet Gynecol, 54, pp.292~304 (2011)
- Sutton G, "Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas(mixed mesodermal tumors)of the uterus : a Gynecologic Oncology Group study", Gynecol Oncol, 96, pp.630~634 (2005)
- Kanthan R, "Uterine carcinosarcomas(malignant mixed mullerian tumours) : a review with special emphasis on the controversies in management", Obstet Gynecol Int, 2011, pp.470795~ (2011)
- Park JY, "The role of pelvic and", or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus, 2010, pp.17, 861~868
- Nemani D, "Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma : a SEER analysis", Gynecol Oncol, 111, pp.82~88 (2008)
- Gonzalez Bosquet J, "The impact of multi-modal therapy on survival for uterine carcinosarcomas", Gynecol Oncol, 116, pp.419~423 (2010)
- Menczer J, "A comparison between different postoperative treatment modalities of uterine carcinosarcoma", Gynecol Oncol, 97, pp.166~170 (2005)
- Wong L, "Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus", Int J Gynecol Cancer, 16, pp.1364~1369 (2006)
- Arend R, "Uterine carcinosarcoma", Curr Opin Oncol, 23, pp.531~536 (2011)
- Garg G, "Stage III uterine carcinosarcoma : 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants", Int J Gynecol Cancer, 21, pp.1606~1612 (2011)
- Inthasorn P, "Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus", Int J Gynecol Cancer, 12, pp.348~353 (2002)
- Ferguson SE, "Prognostic features of surgical stage I uterine carcinosarcoma", Am J Surg Pathol, 31, pp.1653~1661 (2007)
- Huang GS, "Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma", Gynecol Oncol, 107, pp.513~517 (2007)